Amended Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k/a)

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Amendment No. 1

to

FORM 6-K

 

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

 

For the Month of February, 2023

 

011-36000

(Commission File Number)

 

XTL Biopharmaceuticals Ltd.

(Exact name of Registrant as specified in its charter)

 

5 Badner St.

Ramat Gan, Israel, 5218102

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

 

Form 20-F ☒    Form 40-F ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):_____

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):_____

 

 

 

 

 

EXPLANATORY NOTE

 

XTL Biopharmaceuticals Ltd. (the “Company”) is filing this Amendment No. 1 to amend and restate its Report on Form 6-K and all exhibits furnished with the U.S. Securities and Exchange Commission on January 20, 2023 (the “Original Report”). This Amendment No. 1 is being filed solely for the purpose of amending the meeting time from 3:00 PM (Israel Time), on February 23, 2023 to 10:00 AM (Israel Time), on February 23, 2023.

 

1 

 

  

Exhibit Index

 

Exhibit No.		Description
99.1		Notice and Proxy Statement with respect to the Company’s Annual General Meeting of Shareholders
99.2		Proxy Card for holders of ordinary shares with respect to the Company’s Annual General Meeting of Shareholders
99.3		Voting Instruction Card for American Depositary Share holders with respect to the Company’s Annual General Meeting of Shareholders

 

2 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	XTL BIOPHARMACEUTICALS LTD.
Date: February 1, 2023	/s/ Shlomo Shalev
	Shlomo Shalev Chief Executive Officer

 

 

3